Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.53 |
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.52 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 3/20 | 0.51 |
| ▸ | NMBR | P28336 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360713 | 0.93 | SMN1; SMN2 (0.56) | CTSSCTSLCTSKCTSBCAPN1 | |
| SCHEMBL6358735 | 0.88 | CTSK (0.69) | CTSSCTSLCTSKCTSBCAPN1 | |
| SCHEMBL6361024 | 0.85 | SIRT2 (0.62) | CTSSCTSLSIRT2SIRT1 | |
| SCHEMBL6361021 | 0.85 | SIRT2 (0.62) | CTSSCTSLSIRT2SIRT1 | |
| SCHEMBL8750916 | 0.84 | CTSL (0.62) | CTSSCTSLCTSKCTSBCAPN1 | |
| SCHEMBL6358711 | 0.83 | CTSL (0.65) | CTSSCTSLCTSKCTSBCAPN1 | |
| SCHEMBL6361542 | 0.81 | CTSL (0.54) | CTSSCTSLCTSKCTSBCAPN1 | |
| SCHEMBL7140209 | 0.80 | CASP1 (0.60) | CTSSCTSLCTSKCTSBCASP1 | |
| SCHEMBL28707519 | 0.80 | CASP1 (0.60) | CTSSCTSLCTSKCTSBCASP1 | |
| SCHEMBL28707521 | 0.80 | CASP1 (0.60) | CTSSCTSLCTSKCTSBCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858591-B2 | Antibiotic AA 896 analogs | WYETH HOLDINGS CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030087874-A1 | 2-amino-3-hydroxy-3-uridyl-propanoic acid ester derivatives | AMERICAN CYANAMID COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2002086139-A1 | ANTIBIOTIC AA 896 ANALOGS | WYETH HOLDINGS CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087874-A1 | 2-amino-3-hydroxy-3-uridyl-propanoic acid ester derivatives | UMPS, METTL3, FPR3 | CTSS 3983/4885CTSL 2129/4885CTSK 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.